This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Follow up Study(Phase 1) to Evaluate Safety of Autologous Bone Marrow Derived MSCs in Erectile Dysfunction

  • Clinicaltrials.gov identifier

    NCT03933995

  • Recruitment Status

    Recruiting

  • First Posted

    May 1, 2019

  • Last update posted

    October 22, 2020

Study Description

Brief summary:

This is a 5year (+-30 days) long term follow up study to evaluate the safety of autologous bone marrow derived mesenchymal stem cell in erectile dysfunction subject who participated in and completed the Phase 1 trials (refer to ClinicalTrials.gov.Identifier: NCT02344849).

  • Condition or Disease:Erectile Dysfunction
  • Intervention/Treatment: Other: no Intervention
  • Phase: N/A

Detailed Description

This is a 5year (+-30 days) long term follow up study to evaluate the safety of autologous bone marrow derived mesenchymal stem cell in erectile dysfunction subject who participated in and completed the Phase 1 trials (refer to ClinicalTrials.gov.Identifier: NCT02344849). This trial is planned to evaluate the safety of autologous bone marrow derived mesenchymal stem cell in patients with erectile dysfunction subject. Subjects who signed this follow-up observation informed consent form will participate in a safety assessment (tumor marker test, Serious Adverse Events, cancer incidence, recurrence of prostate cancer and vital sign).

Study Design

  • Study Type: Observational
  • Estimated Enrollment: 10 participants
  • Observational Model: Other
  • Time Perspective: Prospective
  • Official Title: Follow up Study(Phase 1) to Evaluate Safety of Autologous Bone Marrow Derived Mesenchymal Stem Cell in Erectile Dysfunction
  • Actual Study Start Date: March 2019
  • Estimated Primary Completion Date: February 2022
  • Estimated Study Completion Date: November 2022

Groups and Cohorts

Groups/Cohorts Intervention/treatment
: Mesenchymal stem cell
Long-term follow up of Mesenchymal stem cell group
Other: no Intervention
no Intervention

Outcome Measures

  • Primary Outcome Measures: 1. Safety Evaluation assessed by Tumor Marker Test. [ Time Frame: 5 year(+-30 days) ]
    Tumor Marker Test(reported in ng/mL): PSA, AFP, CEA Tumor Marker Test is optional item, not mandatory. In this study, tumor markers divided into which are classified as "Normal / Not clinical significant / Clinical significant" abnormalities and analysis the frequency and proportion.
  • 2. Safety Evaluation assessed by Serious Adverse Events, cancer incidence and recurrence of prostate cancer. [ Time Frame: 5 year(+-30 days) ]
    Safety Evaluation assessed by Tumor Marker Test, patient reporting and vital signs For each subject who has had one or more serious adverse events since the ongoing clinical trial, the severity of the adverse reaction should be provided for each causal relationship, and the incidence of serious adverse events should be analyzed.
  • 3. Safety Evaluation assessed by Vital Signs. [ Time Frame: 5 year(+-30 days) ]
    Vital Sign : Blood pressure(reported in mmHg), Pulse(reported in time/min) Vital Sign is optional item, not mandatory. The vital sign values obtained from this study were compared for each group. Baseline statistics (mean, standard deviation, median, maximum, and minimum) are presented, and clinically significant figures are summarized and presented based on the normal range for each value.

Eligibility Criteria

  • Ages Eligible for Study: 20 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: Male
  • Accepts Healthy Volunteers: No
  • Sampling Method: Non-Probability Sample
  • Study Population: Subjects who treated with Mesenchymal stem cell and enrolled the phase 1 study(NCT02344849).

Criteria

Inclusion Criteria:

1. Subjects who treated with Mesenchymal stem cell and enrolled the phase 1
study(NCT02344849).

2. Subjects who can agree to participate in the long term observation study by oneself.

Exclusion Criteria:

- Not Applicable

Contacts and Locations

Contacts

Contact: JIYEOUN JEONG, bachelor 82-02-3496-0134 jyjeong@pharmicell.com

Locations

Korea, Republic of
Asan medical center
Seoul

Sponsors and Collaborators

Pharmicell Co., Ltd.

Investigators

Principal Investigator: Chungsu Kim, Ph.D Asan Medical Center

More Information

  • Responsible Party: Pharmicell Co., Ltd.
  • ClinicalTrials.gov Identifier: NCT03933995 History of Changes
  • Other Study ID Numbers: PMC-P-09
  • First Posted: May 1, 2019 Key Record Dates
  • Last Update Posted: October 22, 2020
  • Last Verified: October 2020
  • Individual Participant
    Data (IPD) Sharing
    Statement:

  • Plan to Share IPD: Undecided
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Erectile Dysfunction